KRAS and lung cancer: Resistance mechanisms to MEK1/2 inhibition in mut KRAS lung cancer involve activation of distinct signaling elements within the KRAS network, such as PI3K, BCL-XL, STAT3, IGFR, EGFR, FGFR1, JNK, ERK or SHP24–12.